Joel Kanter

Nov 16, 2017

Medite Cancer Diagnostics has appointed Joel Kanter to the company’s board of directors as an independent director. Kanter has more than 30 years of experience in the financial services industry, providing financing to businesses that have included startups, early-stage development companies, and larger enterprises. Since 1986, Kanter has served as president of Windy City, a privately held investment firm, and he previously served as the president and CEO of Walnut Financial Services.

More Like This

Sep 20, 2018

Hayden Jeffreys

Hayden Jeffreys has taken on a senior commercial role at Premaitha Health and will be appointed to the company's board in the near future. Most recently, he was the COO of Cambridge Epigenetix, and prior to that, interim CEO of ERBA Diagnostics.

Sep 18, 2018

Sam Tsimikas, Michael Davidson, and others

Boston Heart Diagnostics, a subsidiary of Eurofins Scientific, appointed five members to its scientific advisory board. They are Sam Tsimikas; Michael Davidson; Peter Reaven; Dennis Goodman; and H. Robert Superko. Tsimikas is a cardiologist at the University of California, San Diego specializing in lipoprotein. Davidson is a cardiologist at the University of Chicago with a specialty in omega-3 fatty acid metabolism and clinical use, while Reaven is at the University of Arizona where he researches insulin resistance and diabetes. Goodman specializes in integrative medicine at New York University, and Superko is a founder of Berkeley Heart Lab and a specialist in lipoprotein subfractionization.

Sep 14, 2018

Andy Richards

Owlstone Medical appointed Andy Richards to its board as a non-executive director. Richards, an entrepreneur and business angel, has an established track record in founding and scaling up innovative biotech and health technology companies in the UK, the firm said. His early career spans positions with Imperial Chemical Industries and PA Technology, and he was a founder and executive director of Chiroscience until its merger with Celltech in 1999. Since then, he founded, invested in, and helped to scale more than 25 innovative ventures including Vectura, Arakis, and Cambridge Biotechnology.

Sep 12, 2018

Bob Petrou

Bob Petrou has been named interim CFO and interim principal financial officer of NantHealth, replacing Paul Holt, whose resignation was effective Sept. 11. He will earn about $36,000 per month under a consulting agreement with the company, NantHealth disclosed in a regulatory filing. Petrou most recently was head of finance for the mobility solutions division of smartphone maker BlackBerry. 

Sep 11, 2018

Allan Brown, David Matthews

QuantuMDx appointed Allan Brown as chief operating officer and David Matthews as chief financial officer. Brown was previously COO and a board director at Genedrive where he oversaw the launch of the company's PCR-based platform, also called Genedrive, for diagnosing hepatitis C. He previously was at Qiagen and Tepnel Life Sciences. Matthews was previously CFO at Contextual Genomics and was part of the founding team at GenomeDx Biosciences. 

Sep 11, 2018

Chitra Nayak

Invitae's board of directors this week expanded the number of members on its board to six members and appointed Chitra Nayak as a member. Nayak most recently served as chief operating officer of the real estate technology company Comfy, which was acquired by Siemens in June. Prior to that, Nayak worked at Funding Circle, an online peer-to-peer lending marketplace, and the cloud computing company Nayak will stand for re-election on Invitae's board in 2021.
Sep 11, 2018

Katherine Atkinson

Epic Sciences has appointed Katherine Atkinson as its chief commercial officer, charging her with the development of the firm's global commercial strategy. Atkinson joins Epic with two decades of life science and healthcare experience. Most recently, she served as vice president of business development at Edico Genome, where she established a global channel network and managed strategic partnerships. Prior to Edico she worked for Illumina, overseeing numerous teams, including molecular biology/PCR sales, inside sales, Latin America, and most recently global channel partners. She has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.

Sep 10, 2018

John Howard

MediXall Group has appointed John Howard as senior vice president of laboratory services. He will guide the company as it expands into the clinical laboratory testing market. MediXall expects to begin offering such testing before the end of the year, it said. 

Howard is negotiating with two "major" lab testing companies that would allow it to develop custom health screening lab test panels and profiles, which will include male- and female-specific panels, organ-specific panels, and cancer marker panels. It will also offer toxicology panels for urine drug testing and confirmation and different hormone panels. 

Howard started as a medical technology in clinical labs and later founded and built a clinical laboratory with more than 175 full-time employees. He also invented and founded PocketMD, which provides medical records on credit card-sized CD that can be carried in a wallet or purse.

Sep 10, 2018

Jack Challis

Cancer diagnostics shop Lucence Diagnostics appointed Jack Challis its healthcare analytics director. He will be based in San Francisco and will organize Lucence's streams of genomics data, as well as drive collaborations with research institutes and healthcare providers in the US. Challis cofounded CliniCast, which was acquired by Elekta in 2015. 

Sep 10, 2018

Edwin Hendrick

Biocept has appointed Edwin Hendrick as Senior Vice President and Chief Commercial Officer. Hendrick brings 25 years of sales and commercial leadership experience in the healthcare industry, with senior level commercial and operational positions at a variety of diagnostic and healthcare service companies. 

In his most recent position at GenomeDx, Hendrick developed the company's commercial strategy and launched its commercial offering. Prior to GenomeDx he served as executive vice president of sales and marketing at Plus Diagnostics. He also served as an executive with US Labs and led sales and marketing for Ventana Medical Systems after beginning his career in sales for Abbott Laboratories.

Sep 10, 2018

James Mullen

Thermo Fisher Scientific's board has elected James Mullen as a director, effective Nov. 8. He was appointed to the board's strategy and financing committee, and his term expires at the 2019 annual meeting. Mullen was CEO of Patheon until that firm's acquisition by Thermo Fisher in August 2017. Prior to Patheon, he was CEO and president of Biogen. 

Sep 07, 2018

Nikko Khazana and Mark Mozley

NantHealth has hired Nikko Khazana as senior VP for strategy and business development and Mark Mozley as SVP for global sales. Khazana had previously served as SVP of sales at CompanionDx Reference Lab. Mozley previously led sales efforts for life sciences and global strategic accounts at Clarivate Analytics. 

Sep 06, 2018

Steven Kafka

Steven Kafka has joined the board of directors of ArcherDX. He serves as a venture partner at Third Rock Ventures, and was previously the president and chief operating officer of Foundation Medicine, which is now owned by Roche. Before that, he was the COO and CFO of Aileron Therapeutics and VP of finance at Infinity Pharmaceuticals.

Sep 04, 2018

Katherine Atkinson

Epic Science has appointed Katherine Atkinson as chief commercial officer, tasked with the development of Epic's global commercial strategy.

Atkinson joins Epic with two decades of life science and healthcare experience, most recently as vice president of business development at Edico Genome. Prior to Edico, Atkinson worked for Illumina, where she oversaw a variety of sales teams. She has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.

Aug 31, 2018

Nancy Stratton

Lab accreditation provider COLA announced the appointment of Nancy Stratton as chief executive officer.

Previously, Stratton was CEO of Clinical Pathology Laboratories, the largest division of Sonic Healthcare. She joined CPL in 1995 as a bench technologists, and served in various roles related to quality management, customer service, human resources, risk management, and regulatory and medical legal compliance. She was promoted to CEO of CPL in 2016.

Stratton takes over as CEO of COLA from Doug Beigel, who recently retired after more than 29 years with the organization. In her new role she will be responsible for driving the organization's continued growth and furthering its mission to promote excellence in laboratory medicine and patient care.